1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
AnGes, Inc.

AnGes, Inc.

4563.T
AnGes, Inc.JP flagTokyo Stock Exchange
52.00
JPY
+3.00
- -
20.57BMarket Cap
AnGes, Inc.
4563.T
(Tokyo Stock Exchange)

Recent

price

52.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
10.31
8.48
14.93
16.35
23.86
7.74
8.11
4.79
7.02
3.12
0.34
0.44
0.43
0.81
2.74
2.46
2.25
Revenue per Share
-70.66
-63.25
-57.37
-46.91
-62.12
-74.53
-75.29
-49.38
-34.46
-35.81
-35.33
-92.86
-94.29
-39.29
-119.53
-14.44
-30.61
Basic EPS, GAAP
-67.91
-62.35
-55.52
-48.96
-71.37
-83.87
-79.67
-39.36
-29.59
-20.88
-25.53
-77.82
-71.99
-46.67
-28.43
-16.25
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-131.42
-184.25
-228.38
-216.47
-146.32
-168.29
-184.36
25.89
31.22
27.28
83.66
142.08
51.24
88.05
-39.34
-32.16
70.68
Book Value per Share
148.37
109.04
54.94
115.59
201.37
75.01
60.12
47.51
88.94
115.11
83.64
108.36
45.95
23.02
9.12
8.65
12.7
Tangible Book Value per Share
28
29
30
30
38
56
63
76
87
105
119
147
156
189
235
355
200
Basic Weighted Avg Shares
287
243
445
491
910
430
514
365
610
327
40
64
67
153
644
874
449
Sales/Revenue/Turnover
-700.67
-863.1
-401.65
-277.45
-249.9
-969.88
-926.24
-900.56
-502.46
-1,000.74
-13,999.18
-24,369.16
-24,331.65
-7,822.66
-1,415.31
-588.64
-2,475.71
Operating Margin (%)
102
109
93
60
46
49
67
29
8
7
8
2,426
2,902
3,109
3,372
54
- -
Depreciation Expense
-1,967
-1,815
-1,708
-1,410
-2,369
-4,143
-4,777
-3,765
-2,997
-3,751
-4,210
-13,676
-14,715
-7,438
-28,129
-5,123
-6,108
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
42.64
Effective Tax Rate (%)
-685.64
-745.74
-384.33
-286.92
-260.37
-963.22
-928.85
-1,030.91
-491.21
-1,147.89
-10,524.3
-21,319.14
-21,942.7
-4,861.66
-4,370.31
-586.11
-1,359.35
Profit Margin (%)
3,426
2,034
836
2,959
7,171
3,761
2,989
3,116
7,251
10,549
8,577
14,693
5,573
3,428
1,229
2,143
1,662
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
995
215
109
- -
174
LT Debt
4,288
3,271
1,739
3,544
7,734
4,221
3,869
3,622
7,734
12,055
32,680
38,635
30,425
26,103
2,157
3,076
25,477
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-60.1
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-127.84
-134.63
-65.64
-88.54
-101.76
-60.31
- -
- -
-37.15
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
148
155
162
LT Borrowings
- -
- -
- -
LT Finance Leases
215
197
174
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
198
201
237
Market Capitalization
13,173
13,171
8,781

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
5,921
4,393
3,591
Cash, Cash Equivalents & STI
4,160
2,116
1,821
Accounts Receivable, Net
27
98
200
Inventories
1,566
1,939
1,303
Total Current Liabilities
2,493
2,690
1,929
Payables & Accruals
- -
- -
- -
ST Debt
148
155
162
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.94%
-13.27%
42.64%
Free Cash Flow
19.29%
43.05%
-13.84%
Net Income, GAAP
39.05%
75.89%
-81.79%
Sales/Revenue/Turnover
47.3%
109.92%
35.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
114
234
- -
- -
644
2025
- -
- -
- -
- -
874
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-9.14
- -
- -
- -
-119.53
2025
- -
- -
- -
- -
-14.44
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Pharma Mar, S.A. (PHMMF)
Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO)
Keros Therapeutics, Inc. (KROS)
BioVaxys Technology Corp. (BIOV.CN)
NovAccess Global Inc. (XSNX)
Addex Therapeutics Ltd (ADXN.SW)
Business
AnGes, Inc. (4563.T) develops and commercializes gene medicines and nucleic acid therapeutics for unmet medical needs, primarily focusing on cardiovascular, neurological, and rare diseases. The company offers core products and services including its proprietary Hydrodynamic Gene Delivery technology for non-viral gene transfer; gene therapy candidates such as Collategene (VFGF/HGF plasmid DNA) approved for critical limb ischemia in Japan; preclinical and clinical-stage pipeline assets targeting conditions like hypertrophic cardiomyopathy, moyamoya disease, and diabetic foot ulcers; and nucleic acid medicine platforms like circular RNA and miRNA therapeutics. Operations span research, development, manufacturing, and commercialization primarily in Japan, with clinical trials and partnerships extending to Asia, Europe, and the United States; founded in 1999, AnGes is headquartered in Ibaraki, Osaka, Japan. In recent developments, the company advanced its pipeline with Phase I/II trial initiations for AG2X-314 in hypertrophic cardiomyopathy and reported positive preclinical data for circular RNA-based therapeutics in 2024; it formed strategic alliances with VBL Therapeutics for cancer gene therapy combinations and entered a collaboration with Kyoto University for miRNA research targeting neurological disorders; additionally, AnGes secured funding through a JPY 1.2 billion rights offering in early 2025 and expanded manufacturing capabilities at its Osaka facility to support global clinical supply.